Nuclear Medicine

Annual COBRA Series

On March 24, the Bay Area Young Investigators Meeting for Nuclear Imaging and Therapy met as part of the annual COBRA series.

COBRA Community Connects Nuclear Imaging Investigators in the Bay Area

The Bay Area Community Of Bay area RAdionuclide imagers (COBRA) meeting returned this year and was hosted at UC Davis on May 25, 2022. COBRA, originally conceived in 2006 by the late Bruce Hasegawa, PhD - brilliant investigator, educator and mentor at UCSF – and Ling Shao.

The Future of Molecular Imaging and Prostate Cancer

Because treatment for prostate cancer is highly individualized, molecular imaging technologies are helping to improve the ways in which prostate cancer is diagnosed and treated.

Scientists at UCSF Study Impact of 68Ga-PSMA-11 PET on Post Radical Prostatectomy (RP) Salvage Radiotherapy

Recently, scientists from the UC San Francisco Departments of Radiology and Biomedical Imaging, Urology and Radiation Oncology came together to study the impact of 68Ga-PSMA-11 PET on post radical prostatectomy (RP) salvage radiotherapy.

A Recap of UCSF Radiology at SNMMI 2019

The UC San Francisco Department of Radiology and Biomedical Imaging had a strong presence at the recent Society for Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held June 22-25, 2019 in Anaheim, CA. 

Researchers Assess the Accuracy of 68Ga-PSMA-11 PET in Localizing Prostate Cancer

Scientists at UCSF and UCLA designed a single-arm prospective trial on 635 patients with biochemically recurrent prostate cancer to assess the accuracy of 68Ga-PSMA-11 PET.

Results of Phase I of CTT1057 Human Clinical Trial for Prostate Cancer Now Published

Scientists at UC San Francisco have just conducted the first-in-human Phase I study of CTT1057 in patients with localized and metastatic prostate cancer.

New Study Points to Promising Prognostication for Assessing Diffused Cardiac Allograft Vasculopathy

UCSF Imaging’s Miguel Hernandez Pampaloni, MD, recently authored a study on PET imaging using regadenoson as a stressor to measure reduced myocardal and coronary blood flow for patients after orthotopic heart transplants.

Using Imageable Biomarkers in Drug Development

As medicine has transitioned into the precision era, the scientific community appreciates how important it is to treat patients individually.

Empowering Patients with Innovation

UCSF's PET/MRI technology provides most detailed and accurate information in a single procedure to empower the patient and medical team to make the best treatment decisions.